Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 20, 2026, 7:04 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 49–70 of 70 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: fosaprepitant Clear all
Completed Not applicable Interventional Results available

Fosaprepitant in Patients Receiving Ifosfamide-based Regimen

NCT01490060
View directory record Official record
Conditions
Sarcoma, Chemotherapy-induced Nausea and Vomiting, Effects of Chemotherapy, Adverse Effects of Medical Drugs
Interventions
Fosaprepitant, Dexamethasone, 5HT3 receptor antagonist, Ifosfamide-based chemotherapy (AI), Doxorubicin, Mesna, Ifosfamide, Vincristine
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years to 65 Years
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 11, 2016 · Synced Oct 20, 2026, 7:04 PM EDT
Completed Not applicable Interventional Results available

Comparison of Oral Aprepitant and Transdermal Scopolamine for Preventing Postoperative Nausea and Vomiting

NCT00659737
View directory record Official record
Conditions
Nausea, Vomiting
Interventions
Aprepitant, Scopolamine
Drug
Lead sponsor
Drexel University College of Medicine
Other
Eligibility
18 Years to 65 Years
Enrollment
115 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 15, 2014 · Synced Oct 20, 2026, 7:04 PM EDT
Withdrawn Not applicable Interventional

Prolonged Emend in a Study (NYU 03-67) of Oxaliplatin and Topotecan in Previously Treated Ovarian Cancer

NCT01017809
View directory record Official record
Conditions
Ovarian Cancer
Interventions
Aprepitant
Drug
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years and older · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 18, 2015 · Synced Oct 20, 2026, 7:04 PM EDT
Terminated Not applicable Interventional Results available

Granisetron, Aprepitant, and Dexamethasone in Preventing Nausea and Vomiting in Patients Receiving Chemotherapy for Stage II, III, or IV Ovarian Cancer

NCT01275664
View directory record Official record
Conditions
Nausea and Vomiting, Ovarian Brenner Tumor, Ovarian Clear Cell Cystadenocarcinoma, Ovarian Endometrioid Adenocarcinoma, Ovarian Mucinous Cystadenocarcinoma, Ovarian Seromucinous Carcinoma, Ovarian Serous Cystadenocarcinoma, Stage II Ovarian Cancer, Stage IIA Fallopian Tube Cancer, Stage IIA Ovarian Cancer, Stage IIB Fallopian Tube Cancer, Stage IIB Ovarian Cancer, Stage IIC Fallopian Tube Cancer, Stage IIC Ovarian Cancer, Stage IIIA Fallopian Tube Cancer, Stage IIIA Ovarian Cancer, Stage IIIA Primary Peritoneal Cancer, Stage IIIB Fallopian Tube Cancer, Stage IIIB Ovarian Cancer, Stage IIIB Primary Peritoneal Cancer, Stage IIIC Fallopian Tube Cancer, Stage IIIC Ovarian Cancer, Stage IIIC Primary Peritoneal Cancer, Stage IV Fallopian Tube Cancer, Stage IV Ovarian Cancer, Stage IV Primary Peritoneal Cancer, Undifferentiated Ovarian Carcinoma
Interventions
Adjuvant Therapy, Aprepitant, Carboplatin, Cisplatin, Dexamethasone, Granisetron Transdermal Patch, Management of Therapy Complications, Questionnaire Administration
Procedure · Drug · Other
Lead sponsor
Gynecologic Oncology Group
Network
Eligibility
18 Years and older · Female only
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2011
U.S. locations
2
States / cities
Hinsdale, Illinois • Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated May 22, 2018 · Synced Oct 20, 2026, 7:04 PM EDT
Completed Not applicable Interventional Results available

Aprepitant's Effect on Drug Metabolism in Multi-Day Combination (CHOP/R-CHOP) Chemotherapy Regimen in Lymphoma Patients

NCT00651755
View directory record Official record
Conditions
Lymphoma
Interventions
Aprepitant, Cyclophosphamide, Doxorubicin, Vincristine, Prednisone, Rituximab, Ondansetron
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 2, 2013 · Synced Oct 20, 2026, 7:04 PM EDT
Terminated Phase 3 Interventional Results available

Olanzapine for the Prevention of Chemotherapy Induced Nausea and Vomiting in Gynecologic Oncology Patients

NCT04503668
View directory record Official record
Conditions
Gynecologic Cancer
Interventions
Ondansetron, Dexamethasone, Neurokinin-1 Receptor Antagonist (NK1-RA), Olanzapine, Compazine
Drug
Lead sponsor
University of Michigan Rogel Cancer Center
Other
Eligibility
18 Years to 89 Years · Female only
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Jun 18, 2025 · Synced Oct 20, 2026, 7:04 PM EDT
Terminated Early Phase 1 Interventional

A Pilot Study of Induction Chemotherapy Followed by Surgery for Locally Advanced Resectable Head and Neck Cancer

NCT01111942
View directory record Official record
Conditions
Head and Neck Cancer
Interventions
radiation combined with weekly carboplatin, conservation surgery
Other · Procedure
Lead sponsor
Southern Illinois University
Other
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
1
States / cities
Springfield, Illinois
Source: ClinicalTrials.gov public record
Updated Aug 5, 2015 · Synced Oct 20, 2026, 7:04 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Comparison of Aprepitant Versus Aprepitant and Transdermal Scopolamine for Preventing Postoperative Nausea and Vomiting

NCT00717054
View directory record Official record
Conditions
Nausea, Vomiting
Interventions
Aprepitant, Scopolamine
Drug
Lead sponsor
Drexel University
Other
Eligibility
18 Years to 65 Years
Enrollment
115 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2010
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 20, 2014 · Synced Oct 20, 2026, 7:04 PM EDT
Terminated Phase 4 Interventional Results available

Aprepitant for Prevention of Postoperative Nausea and Vomiting in Elective Hysterectomy

NCT00888329
View directory record Official record
Conditions
Postoperative Nausea and Vomiting
Interventions
Aprepitant, Placebo
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older · Female only
Enrollment
256 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
1
States / cities
Phoenix, Arizona
Source: ClinicalTrials.gov public record
Updated Mar 30, 2012 · Synced Oct 20, 2026, 7:04 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

Combination Antiemetic Regimen for Prevention of PONV in Breast Surgery Patients

NCT00738621
View directory record Official record
Conditions
Postoperative Nausea and Vomiting
Interventions
Aprepitant, Dexamethasone, Ondansetron, Aprepitant, Dexamethasone, Placebo
Drug
Lead sponsor
Scott and White Hospital & Clinic
Other
Eligibility
18 Years to 65 Years · Female only
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2010
U.S. locations
1
States / cities
Temple, Texas
Source: ClinicalTrials.gov public record
Updated Dec 19, 2013 · Synced Oct 20, 2026, 7:04 PM EDT
Completed Phase 3 Interventional Results available

A Prospective, Multicenter, Study of APF530 (Granisetron) SC for Prevention of CINV in Patients Receiving HEC

NCT02106494
View directory record Official record
Conditions
Chemotherapy-induced Nausea and Vomiting
Interventions
APF530, Ondansetron, Ondansetron placebo, APF530 placebo, Fosaprepitant, Dexamethasone
Drug
Lead sponsor
Heron Therapeutics
Industry
Eligibility
18 Years to 87 Years
Enrollment
942 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
7
States / cities
Phoenix, Arizona • Downey, California • Riverside, California + 4 more
Source: ClinicalTrials.gov public record
Updated Mar 2, 2026 · Synced Oct 20, 2026, 7:04 PM EDT
Completed Phase 3 Interventional Results available

Study of FOND Versus FOND+O for the Prevention of CINV in Hematology Patients Receiving Highly Emetogenic Chemotherapy Regimens

NCT02635984
View directory record Official record
Conditions
Complications of Bone Marrow Transplant, Hematologic Neoplasms
Interventions
Olanzapine, Placebo
Drug
Lead sponsor
Augusta University
Other
Eligibility
18 Years and older
Enrollment
108 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Augusta, Georgia
Source: ClinicalTrials.gov public record
Updated Aug 20, 2018 · Synced Oct 20, 2026, 7:04 PM EDT
Completed Phase 2 Interventional Results available

Emend and Ondansetron Compared to Ondansetron Alone to Prevent CINV in Glioma Patients Receiving Temozolomide

NCT01450826
View directory record Official record
Conditions
Nausea, Vomiting, Glioma
Interventions
aprepitant, ondansetron
Drug
Lead sponsor
Katy Peters
Other
Eligibility
18 Years and older
Enrollment
136 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 26, 2018 · Synced Oct 20, 2026, 7:04 PM EDT
Completed Phase 3 Interventional Results available

Antiemetic Therapy With or Without Olanzapine in Preventing Chemotherapy-Induced Nausea and Vomiting in Patients With Cancer Receiving Highly Emetogenic Chemotherapy

NCT02116530
View directory record Official record
Conditions
Hematopoietic/Lymphoid Cancer, Nausea and Vomiting, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
Olanzapine, Chemotherapy (cisplatin or cyclophosphamide and doxorubicin), Antiemetic treatment (ondansetron or granisetron or palonosetron; plus dexamethasone; plus fosaprepitant or aprepitant), Placebo
Drug · Other
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older
Enrollment
401 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
177
States / cities
Anchorage, Alaska • Burbank, California • Dublin, California + 109 more
Source: ClinicalTrials.gov public record
Updated Jan 28, 2025 · Synced Oct 20, 2026, 7:04 PM EDT
Completed Phase 1 Interventional Results available

Study of Proton Therapy in Adjuvant Pancreatic Cancer

NCT03885284
View directory record Official record
Conditions
Resected Pancreatic Adenocarcinoma
Interventions
mFOLFIRINOX, Proton beam radiation
Drug · Radiation
Lead sponsor
Georgetown University
Other
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Oct 24, 2024 · Synced Oct 20, 2026, 7:04 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Selinexor Plus High-Dose Melphalan (HDM) Before Autologous Hematopoietic Cell Transplantation for Multiple Myeloma

NCT02780609
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Selinexor, Melphalan, Dexamethasone, Autologous Hematopoietic Cell Transplantation (HCT), Fosaprepitant
Drug · Procedure
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Nov 4, 2022 · Synced Oct 20, 2026, 7:04 PM EDT
Recruiting Phase 2Phase 3 Interventional

Antiemetic Fosaprepitant To Remedy Nausea and Vomiting

NCT06382012
View directory record Official record
Conditions
Nausea and Vomiting, Nausea, Vomiting
Interventions
Fosaprepitant 150 mg, Ondansetron 4 mg
Drug
Lead sponsor
Montefiore Medical Center
Other
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated May 18, 2026 · Synced Oct 20, 2026, 7:04 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Aprepitant Versus Ondansetron in Preoperative Triple-therapy Treatment of Nausea and Vomiting

NCT01474915
View directory record Official record
Conditions
Postoperative Nausea and Vomiting (PONV), Nausea
Interventions
Aprepitant, Ondansetron, Promethazine, Dexamethasone
Drug
Lead sponsor
Sergio Bergese
Other
Eligibility
18 Years to 85 Years
Enrollment
122 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2013
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Dec 3, 2013 · Synced Oct 20, 2026, 7:04 PM EDT
Completed Phase 3 Interventional Results available

Prevention of Delayed Nausea A Phase III Double-Blind Placebo-Controlled Clinical Trial

NCT00475085
View directory record Official record
Conditions
Nausea
Interventions
aprepitant, dexamethasone, granisetron hydrochloride, palonosetron hydrochloride, prochlorperazine, placebo
Drug
Lead sponsor
Joseph Roscoe
Other
Eligibility
18 Years and older
Enrollment
1,021 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2006
U.S. locations
16
States / cities
Mobile, Alabama • Decatur, Illinois • Wichita, Kansas + 13 more
Source: ClinicalTrials.gov public record
Updated Nov 10, 2015 · Synced Oct 20, 2026, 7:04 PM EDT
Terminated Phase 2 Interventional Results available

Rolapitant Hydrochloride in Preventing Nausea/Vomiting in Patients With Sarcoma Receiving Chemotherapy

NCT02732015
View directory record Official record
Conditions
Locally Advanced Sarcoma
Interventions
Dexamethasone, Doxorubicin, Fosaprepitant Dimeglumine, Ifosfamide, Laboratory Biomarker Analysis, Mesna, Ondansetron, Questionnaire Administration, Rolapitant Hydrochloride, Vincristine Sulfate
Drug · Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years to 65 Years
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 9, 2021 · Synced Oct 20, 2026, 7:04 PM EDT
Not listed Not applicable Interventional

Oral Aprepitant and Lower Dose Dexamethasone Versus Aprepitant Alone for Preventing Postoperative Nausea and Vomiting (PONV) After Elective Laparoscopic Surgeries

NCT00835965
View directory record Official record
Conditions
Nausea, Vomiting
Interventions
Dexamethasone, Aprepitant, Placebo Dexamethasone
Drug
Lead sponsor
Main Line Health
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2009
U.S. locations
1
States / cities
Wynnewood, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 4, 2009 · Synced Oct 20, 2026, 7:04 PM EDT
Completed Phase 2 Interventional Results available

Phase II Trial of Aprepitant & Palonosetron for CINV Prevention w FOLFOX

NCT00381862
View directory record Official record
Conditions
Colorectal Cancer, Nausea and Vomiting
Interventions
aprepitant, dexamethasone, fluorouracil, irinotecan hydrochloride, leucovorin calcium, oxaliplatin, palonosetron hydrochloride, quality-of-life assessment
Drug · Procedure
Lead sponsor
OHSU Knight Cancer Institute
Other
Eligibility
18 Years to 120 Years
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
6
States / cities
Savannah, Georgia • Hilo, Hawaii • Harvey, Illinois + 3 more
Source: ClinicalTrials.gov public record
Updated Jun 12, 2017 · Synced Oct 20, 2026, 7:04 PM EDT